In vitro activity of LY333328 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and penicillin-resistant Streptococcus pneumoniae

Robin Patel, Mark S. Rouse, Kerryl E. Piper, Franklin R. Cockerill, James M. Steckelberg

Research output: Contribution to journalArticle

26 Scopus citations


We report the activity of LY333328 against 35 clinical isolates of vancomycin-resistant enterococci (including organisms carrying the vanA, vanB, vanC-1, and vanC-2/3 genes, as determined by PCR), 33 clinical isolates of methicillin-resistant S. aureus, and 29 clinical isolates of high-level penicillin-resistsant S. pneumoniae. All isolates of vancomycin-resistant enterococci were inhibited by 2 μg/mL LY333328, and 8 μg/mL LY333328 was bactericidal against all isolates tested. All isolates of methicillin-resistant S. aureus were inhibited by 1 μg/mL LY333328, and 4 μg/mL LY333328 was bactericidal against all methicillin-resistant S. aureus isolates tested. All isolates of penicillin-resistant S. pneumoniae were inhibited by <0.125 μg/mL LY333328, and 0.25 μg/mL LY333328 was bactericidal against S. pneumoniae isolates tested. LY333328 is a promising new glycopeptide antimicrobial agent.

Original languageEnglish (US)
Pages (from-to)89-92
Number of pages4
JournalDiagnostic Microbiology and Infectious Disease
Issue number2
StatePublished - Feb 1998


ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology and Allergy
  • Virology
  • Parasitology
  • Microbiology
  • Immunology
  • Applied Microbiology and Biotechnology

Cite this